Multidrug-Resistant Tuberculosis Presenting as Miliary Tuberculosis without Immune Suppression: A Case Diagnosed Rapidly with the Genotypic Line Probe Assay Method

Yousang Ko, M.D. 1,* , Ho Young Lee, M.D. 1,* , Young Seok Lee, M.D. 1, Junwhi Song, M.D. 2, Mi-Yeong Kim, M.D. 1, Hyun-Kyung Lee, M.D. 1, Jeong Hwan Shin, M.D. 3, Seok Jin Choi, M.D. 4 and Young-Min Lee, M.D. 1

1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, 2Department of Pulmonology, Samsung Changwon Medical Center, Sungkyunkwan University School of Medicine, Changwon, Departments 3Laboratory Medicine and 4Radiology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

Miliary tuberculosis (TB) is a rare extrapulmonary form of TB, and there have been only two reports of miliary TB associated with infection with multidrug-resistant (MDR)-TB pathogen in an immunocompetent host. A 32-year-old woman was referred to our hospital because of abnormal findings on chest X-ray. The patient was diagnosed with MDR-TB by a line probe assay and was administered proper antituberculous drugs. After eight weeks, a solid-media drug sensitivity test revealed that the pathogen was resistant to ethambutol and streptomycin in addition to isoniazid and rifampicin. The patient was then treated with effective antituberculous drugs without delay after diagnosis of MDR-TB. To the best of our knowledge, this is the first case of miliary TB caused by MDR-TB pathogen in Korea.

Keywords: Tuberculosis, Multidrug-Resistant; Tuberculosis, Miliary; Molecular Probe Techniques

Introduction

Although global cooperative efforts have been made to reduce the global incidence of drug-susceptible tuberculosis (TB), multidrug-resistant (MDR)-TB has emerged worldwide over the past 20 years. 1-3 Miliary TB is a clinically rare form of TB and data from the US Centers for Disease Control and Prevention in 2010 indicated that less than 2% of all cases of TB were classified as miliary TB. 4

There are several reports of miliary TB caused by MDR-TB pathogen in immunocompromised hosts such as people with acquired immunodeficiency syndrome or on infliximab therapy 5,6, but there are only two previous reports of miliary TB caused by MDR-TB pathogen in an immunocompetent host. 7,8

Here, we report a documented case of MDR-TB presenting as miliary TB in an immunocompetent patient. This case was rapidly diagnosed as MDR-TB by the molecular reverse
hybridization-based line probe assay (LPA) genotypic method, meaning that the patient was administered appropriately modified effective antituberculous drugs without delay. We wish to emphasize the possibility of MDR-TB even in an immunocompetent patient with miliary TB in circumstances where moderate levels of resistance in the TB patient population would be predicted.

**Case Report**

In May 2013, a 32-year-old woman was referred to our hospital because of abnormal findings on a chest X-ray. She had been healthy until one month before, when a cough and intermittent chills developed. She was a current smoker but denied use of illicit drugs or other relevant medical history.

She had no familial history of TB and denied a contact with a person with TB infection. She acted with a touring company for five years. On examination, she appeared well. Her body weight was 69 kg, height 168.2 cm, temperature 36.2°C, blood pressure 123/80 mm Hg, pulse 78 beats per minute, and oxygen saturation 100% while breathing ambient air. Laboratory results were normal. A human immunodeficiency virus antibody test was negative.

A chest radiograph and computed tomography scan of the chest revealed uniform-sized small nodules randomly distributed throughout both lungs (Figure 1). We performed bronchoalveolar lavage (BAL) and transbronchial lung biopsy at the anterior segment of the right upper lung.

The next day, the microbiological investigation of BAL fluid by TB polymerase chain reaction gave a positive result. We therefore diagnosed the patient with miliary TB and treated her with isoniazid, rifampicin, ethambutol, and pyrazinamide. She was discharged without complication. Two weeks after bronchoscopy, *Mycobacterium tuberculosis* was isolated from the liquid media of the BAL specimen. We then performed a reverse hybridization-based LPA and a solid-media drug sensitivity test (DST). The patient complained of myalgia and chills for two weeks.

One day later, the LPA revealed that the pathogen had mutations in the *katG* and *rpoB* genes (Figure 2), so the patient was suspected to have miliary TB caused by MDR-TB pathogen. Her antituberculous treatment was changed to ethambutol, pyrazinamide, kanamycin, moxifloxacin, prothionamide,
and cycloserine. A solid-media DST performed in the Korean Institute of TB using the absolute concentration method was consistent with MDR-TB eight weeks after the isolation of Mycobacterium tuberculosis from the BAL. The solid-media DST report was delayed because of contamination of the specimen. It showed the pathogen to be resistant to ethambutol and streptomycin in addition to isoniazid and rifampicin.

Finally, the patient was diagnosed with miliary TB caused by MDR-TB pathogen. Her antituberculous therapy has been maintained with the regimen described above with the exception of ethambutol. Three months after beginning treatment for miliary TB, the patient did not complain of any symptoms and the follow-up chest plain X-ray showed that the disease had partially resolved compared with the initial presentation (Figure 3).

Discussion

The overall incidence of TB has been reported to be slowly decreasing since 2004 through the World Health Organization (WHO) Stop TB Strategy, but there is no definitive evidence that the incidence of MDR-TB is decreasing despite this global effort. Despite great efforts in several countries including South Korea that have led to a slow decrease in the overall incidence of TB, surveillance indicates that the incidence of MDR-TB is rising. Moreover, prevalence of MDR-TB may be suggested three times greater than incidence because MDR-TB patients often live for several years before succumbing to the disease.

It is known that a number of risk factors for MDR-TB have been critical in the emergence. Almost all are related to poorly functioning National Tuberculosis Program. Other important risk factors are associated with the supply or quality of the drugs, the possible inadequate drug intake by patients, and others, such as the influence of the private sector, deficient infection control in health centers and hospitals, and the possible high prevalence of highly virulent MDR-TB strains of M. tuberculosis. Many other risk factors for MDR-TB have been also identified: previous TB treatment, irregular treatment, female sex, non-permanent residents, urban migration, urban residence, frequent travelers, younger age, lack of a sewage system in the home, alcoholism plus smoking, and lung cavities. In our case, the patient was only associated with female sex, urban residence, and young age of risk factors for MDR-TB. We repeatedly performed a human immunodeficiency virus antibody test and peripheral CD4/CD8 ratio but the result was unremarkable.

MDR-TB can also cause miliary TB, but the incidence of MDR-TB in miliary TB infection is completely unknown because of the low incidence of this rare extrapulmonary form of TB. There have been several case reports of miliary TB caused by MDR-TB pathogen in an immunocompromised host, but only two reports in an immunocompetent host. The reason for the high incidence of miliary TB in immunocompromised patients is thought to be the combination of an inadequate immune response and a lack of effective antituberculous treatment.

It is known that in 30% to 65% of cases, microbiological confirmation of miliary TB is on the basis of culture of the pathogen from a respiratory specimen. In this case, we could detect MDR-TB more rapidly using a molecular (genotypic) method than using conventional (phenotypic) methods such as solid- and liquid-media DST, so we could administer adequate and effective antituberculous treatment without delay. The reverse hybridization-based LPA has been developed for direct detection of MDR-TB strains in clinical specimens. The GenoType MTBDRplus (Hain Lifescience, Nehren, Germany) assay detects MDR-TB by simultaneously detecting mutations in hot spot regions of the rpoB gene to indicate rifampicin resistance and mutations in katG315 and inhA regulatory regions to indicate isoniazid resistance. The LPA has performed satisfactorily in several clinical settings for detection of MDR-TB in clinical samples. Therefore, it can be considered that a rapid genetic DST such as the LPA is a suitable alternative method for early detection of MDR-TB in miliary TB.

In conclusion, the possibility of MDR-TB should be considered in miliary TB despite its rarity, especially in regions such as Korea with moderate levels of drug resistance among TB patients. In addition, a molecular DST such as the LPA can be a good method to diagnose MDR-TB more rapidly in cases of extrapulmonary TB infection such as miliary TB. To the best of our knowledge, this is the first documented case of miliary TB caused by MDR-TB pathogen in Korea.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-43.
2. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28.
3. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva: WHO; 2006.
4. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2010. Atlanta: Centers for Disease Control and Prevention; 2011.

5. Daikos GL, Utramechandani RB, Tuda C, Fischl MA, Miller N, Cleary T, et al. Disseminated miliary tuberculosis of the skin in patients with AIDS: report of four cases. Clin Infect Dis 1998;27:205-8.

6. Hill AR, Premkumar S, Brustein S, Vaidya K, Powell S, Li PW, et al. Disseminated tuberculosis in the acquired immunodeficiency syndrome era. Am Rev Respir Dis 1991;144:1164-70.

7. Shah A, Panjabi C, Maurya V, Khanna P. Multidrug resistant miliary tuberculosis and Pott's disease in an immunocompetent patient. Saudi Med J 2004;25:1468-70.

8. Sasse J, Teichmann D. Disseminated multiorgan MDR-TB resistant to virtually all first-line drugs. Eur Respir Rev 2009;18:291-4.

9. Kim SY, Kim HJ, Kim CK, Yoon HR, Bae HG, Lee SH, et al. The recent status of multidrug- and extensively drug-resistant tuberculosis in Korea. Tuberc Respir Dis 2010;68:146-54.

10. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010;14:382-90.

11. Kim JH, Langston AA, Gallis HA. Miliary tuberculosis: epidemiology, clinical manifestations, diagnosis, and outcome. Rev Infect Dis 1990;12:583-90.

12. Ray S, Talukdar A, Kundu S, Khanra D, Sonthalia N. Diagnosis and management of miliary tuberculosis: current state and future perspectives. Ther Clin Risk Manag 2013;9:9-26.

13. Ahmad S, Mokaddas E. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Respir Med 2009;103:1777-90.

14. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2005;5:62.

15. Bwanga F, Hoffner S, Haile M, Joloba ML. Direct susceptibility testing for multidrug resistant tuberculosis: a meta-analysis. BMC Infect Dis 2009;9:67.